205 related articles for article (PubMed ID: 21190649)
21. How do socio-demographic and clinical factors interact with adherence attitude profiles in schizophrenia? A cluster-analytical approach.
Beck EM; Cavelti M; Wirtz M; Kossowsky J; Vauth R
Psychiatry Res; 2011 May; 187(1-2):55-61. PubMed ID: 21074860
[TBL] [Abstract][Full Text] [Related]
22. Choosing antipsychotic maintenance therapy--a naturalistic study.
Tavcar R; Dernovsek MZ; Zvan V
Pharmacopsychiatry; 2000 Mar; 33(2):66-71. PubMed ID: 10761822
[TBL] [Abstract][Full Text] [Related]
23. Nonadherence to antipsychotics: the role of positive attitudes towards positive symptoms.
Moritz S; Hünsche A; Lincoln TM
Eur Neuropsychopharmacol; 2014 Nov; 24(11):1745-52. PubMed ID: 25444234
[TBL] [Abstract][Full Text] [Related]
24. Medication adherence and subjective weight perception in patients with first-episode psychotic disorder.
Wong MM; Chen EY; Lui SS; Tso S
Clin Schizophr Relat Psychoses; 2011 Oct; 5(3):135-41. PubMed ID: 21983497
[TBL] [Abstract][Full Text] [Related]
25. Long-acting injectable antipsychotics in the elderly: guidelines for effective use.
Masand PS; Gupta S
Drugs Aging; 2003; 20(15):1099-110. PubMed ID: 14651433
[TBL] [Abstract][Full Text] [Related]
26. Antipsychotic medication adherence: is there a difference between typical and atypical agents?
Dolder CR; Lacro JP; Dunn LB; Jeste DV
Am J Psychiatry; 2002 Jan; 159(1):103-8. PubMed ID: 11772697
[TBL] [Abstract][Full Text] [Related]
27. Financial incentives for improving adherence to maintenance treatment in patients with psychotic disorders (Money for Medication): a multicentre, open-label, randomised controlled trial.
Noordraven EL; Wierdsma AI; Blanken P; Bloemendaal AF; Staring AB; Mulder CL
Lancet Psychiatry; 2017 Mar; 4(3):199-207. PubMed ID: 28236956
[TBL] [Abstract][Full Text] [Related]
28. Compliance and schizophrenia: the predictive potential of insight into illness, symptoms, and side effects.
Kao YC; Liu YP
Compr Psychiatry; 2010; 51(6):557-65. PubMed ID: 20965300
[TBL] [Abstract][Full Text] [Related]
29. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.
Perkins DO; Johnson JL; Hamer RM; Zipursky RB; Keefe RS; Centorrhino F; Green AI; Glick IB; Kahn RS; Sharma T; Tohen M; McEvoy JP; Weiden PJ; Lieberman JA;
Schizophr Res; 2006 Mar; 83(1):53-63. PubMed ID: 16529910
[TBL] [Abstract][Full Text] [Related]
30. Monitoring treatment and managing adherence in schizophrenia.
Marder SR
J Clin Psychiatry; 2013 Oct; 74(10):e21. PubMed ID: 24229761
[TBL] [Abstract][Full Text] [Related]
31. [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications].
Misdrahi D; Llorca PM; Lançon C; Bayle FJ
Encephale; 2002; 28(3 Pt 1):266-72. PubMed ID: 12091789
[TBL] [Abstract][Full Text] [Related]
32. A Study of the Impact of Cannabis on Doses of Discharge Antipsychotic Medication in Individuals with Schizophrenia or Schizoaffective Disorder.
Babatope T; Chotalia J; Elkhatib R; Mohite S; Shah J; Goddu S; Patel RA; Aimienwanu OR; Patel D; Makanjuola T; Okusaga OO
Psychiatr Q; 2016 Dec; 87(4):729-737. PubMed ID: 26875104
[TBL] [Abstract][Full Text] [Related]
33. Psychiatrist and patient responses to suspected medication nonadherence in schizophrenia spectrum disorders.
Hamann J; Lipp ML; Christ-Zapp S; Spellmann I; Kissling W
Psychiatr Serv; 2014 Jul; 65(7):881-7. PubMed ID: 24686753
[TBL] [Abstract][Full Text] [Related]
34. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data.
Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
Adv Ther; 2018 Oct; 35(10):1612-1625. PubMed ID: 30206822
[TBL] [Abstract][Full Text] [Related]
35. Encouraging patients to take medication as prescribed. Two recent reviews offer advice about assessing and improving treatment adherence.
Harv Ment Health Lett; 2010 Jan; 26(7):4-5. PubMed ID: 20213933
[No Abstract] [Full Text] [Related]
36. Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study.
Baloush-Kleinman V; Levine SZ; Roe D; Shnitt D; Weizman A; Poyurovsky M
Schizophr Res; 2011 Aug; 130(1-3):176-81. PubMed ID: 21636254
[TBL] [Abstract][Full Text] [Related]
37. [Therapeutic alliance, a stake in schizophrenia].
Charpentier A; Goudemand M; Thomas P
Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
[TBL] [Abstract][Full Text] [Related]
38. The impact of self-stigmatization on medication attitude in schizophrenia patients.
Feldhaus T; Falke S; von Gruchalla L; Maisch B; Uhlmann C; Bock E; Lencer R
Psychiatry Res; 2018 Mar; 261():391-399. PubMed ID: 29353769
[TBL] [Abstract][Full Text] [Related]
39. Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study.
Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa-McMillan A
J Clin Psychiatry; 2012 Sep; 73(9):1224-33. PubMed ID: 22938760
[TBL] [Abstract][Full Text] [Related]
40. Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia.
Achtyes E; Simmons A; Skabeev A; Levy N; Jiang Y; Marcy P; Weiden PJ
BMC Psychiatry; 2018 Sep; 18(1):292. PubMed ID: 30223804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
